PE-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63)
抗体来源（Source）
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
应用（Application）
Flow Cytometry (Detection the expression of CD19 on Human cells).
克隆号（Clone）
FMC63
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG2a | kappa
特异性（Specificity）
This product is a specific antibody specifically reacts with CD19 protein.
种属反应性（Reactivity）
Human
免疫原（Immunogen）
Human prolymphocytic leukaemia cell line JVM3.
偶联（Conjugate）
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
同型对照（Isotype Control）
The Isotype control is sold separately and you can search for Cat. No. DNP-PM487 for product information.
推荐稀释比（Recommended Dilution）
1:50
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.03% Proclin 300, pH7.4, 0.2% BSA with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 12 months after reconstitution.
2-8 °C for 12 months after reconstitution.
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
关键字： CD19抗体;FMC63;FMC63抗体;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。